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RESEARCH ARTICLE
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Abstract
Vascular pathophysiological changes after haemorrhagic stroke, such as phenotypic modu-
lation of the cerebral arteries and cerebral vasospasms, are associated with delayed cere-
bral ischemia (DCI) and poor outcome. The only currently approved drug treatment shown
to reduce the risk of DCI and improve neurologic outcome after aneurysmal subarachnoid
haemorrhage (SAH) is nimodipine, a dihydropyridine L-type voltage-gated Ca2+ channel
blocker. MEK1/2 mediated transcriptional upregulation of contractile receptors, including
endothelin-1 (ET-1) receptors, has previously been shown to be a factor in the pathology of
SAH. The aim of the study was to compare intrathecal and subcutaneous treatment regi-
mens of nimodipine and intrathecal treatment regimens of U0126, a MEK1/2 inhibitor, in
a single injection experimental rat SAH model with post 48 h endpoints consisting of wire
myography of cerebral arteries, flow cytometry of cerebral arterial tissue and behavioural
evaluation. Following ET-1 concentration-response curves, U0126 exposed arteries had a
significantly lower ET-1max than vehicle arteries. Arteries from both the intrathecal- and sub-
cutaneous nimodipine treated animals had significantly higher ET-1max contractions than
the U0126 arteries. Furthermore, Ca2+ concentration response curves (precontracted with
ET-1 and in the presence of nimodipine) showed that nimodipine treatment could result in
larger nimodipine insensitive contractions compared to U0126. Flow cytometry showed
decreased protein expression of the ETB receptor in U0126 treated cerebral vascular
smooth muscle cells compared to vehicle. Only U0126 treatment lowered ET-1max contrac-
tions and ETB receptor levels, as well as decreased the contractions involving nimodipine-
insensitive Ca2+ channels, when compared to both intrathecal and subcutaneous nimodi-
pine treatment. This indicate that targeting gene expression might be a better strategy than
blocking specific receptors or ion channels in future treatments of SAH.
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Introduction
Aneurysmal subarachnoid haemorrhage (SAH), is a type of haemorrhagic stroke responsible
for around 5% of stroke incidents, but with an approx. 50% short term mortality rate and with
remaining survivors having reduced quality of life due to cognitive impairments [1, 2]. SAH
has a multiphase course; consisting of an early phase with a rapid leakage of blood into the sub-
arachnoid space causing a rise in intracranial pressure (ICP) and a drop in cerebral blood flow
(CBF), depriving the brain of oxygen and glucose, causing cerebral ischemia and brain dam-
age, sometimes referred to as early brain injury [3].
In humans, a secondary delayed phase occurs days after the initial insult and causes further
cerebral ischemia and brain damage, sometimes referred to as delayed brain injury. An impor-
tant mechanism associated with this delayed brain injury is delayed cerebral ischemia (DCI),
which consists of various pathophysiological changes; including inflammation [4], oedema [5],
blood-brain barrier disruption and vascular phenotypic changes associated with remodelling
and narrowing of the cerebral arteries, often referred to as delayed cerebral vasospasm (CVS)
[3, 6]. Mechanisms thought to contribute to the development of DCI include cerebral vascular
dysfunction (both macro- and microvascular), micro thrombosis, cortical spreading depolari-
zations and neuroinflammation [3].
The only current drug treatment known to reduce the risk of DCI is oral administration of
nimodipine, an inhibitor of voltage gated calcium channels [7, 8]. Current guidelines specify
that all SAH patients should be treated with nimodipine because it has been shown to improve
neurological outcome, but it does not per se prevent cerebral vasospasm. [9, 10]. Targeting
DCI has for decades been the aim of many clinical studies, with a focus on vascular contractil-
ity. Several experimental treatments with e.g. endothelin receptor antagonists have been used
to relieve CVS and delayed cerebral ischemia, but with poor results on functional outcomes,
including the specific endothelin receptor A (ETA) and B (ETB) antagonist clazosentan [11–
13].
For several years, we have worked on an alternative hypothesis, focusing on the an upregu-
lation of contractile proteins in the cerebral vasculature as the source of DCI [14, 15]. In one
study, clazosentan was compared directly with the MEK1/2 inhibitor U0126. Here, U0126
reduced the upregulation of contractile receptor subtypes after experimental SAH and was
shown to result in better neurological outcome [16]. The effect of U0126 treatment has, in
addition to reducing vasoconstriction and improving neurological outcome [15], also been
shown to reduce pro-inflammatory cytokine activity (TNFα, IL-1β and IL-6) and reduce
expression of matrix metalloproteinases (MMP-9) [17, 18] after experimental SAH. MMP-9
and MMP-2 have been shown to increase blood-brain barrier permeability by disrupting tight
junctions, as well as being a factor in cerebral aneurysm formation [19].
We hypothesize that vascular phenotypic modulation is important for understanding the
detrimental effects of DCI following SAH. The disruption of normal vascular smooth muscle
cell (VSMC) contractility is known to occur by signalling through the MEK/ERK1/2 pathway,
by which dedifferentiation in VSMC is driven from a contractile-quiescent- to a migratory-
proliferative-synthetic phenotype [20]. In this study we compared various treatment regimens
of the current drug treatment of DCI (nimodipine) with the MEK1/2 inhibitor U0126.
Materials and methods
Rat subarachnoid haemorrhage model
Fifty male Sprague-Dawley rats (NTac:SD) (290–386 g, purchased from Taconic (Denmark),
were maintained at a 12/12-h light-dark cycle (with dark beginning at 7 a.m.) and housed at a
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constant temperature (22 ± 2˚C) and humidity (55 ± 10%), with food and water ad libitum.
Rats were generally housed in Eurostandard cages (Type VI with 123-Lid) 2–6 together and
single housed (Type III with 123-Lid) after undergoing the procedure. There was no post-sur-
gery mortality in this study. 50 of 77 operated animals were included in the study, with 26
being excluded due to not meeting the surgical inclusion criteria (S1 Fig). Additionally, one
animal was excluded from the Sham group due to the artery spontaneously contracting before
the addition of ET-1 in the myograph.
All procedures were approved by the Danish Animal Experimentation Inspectorate (license
no. 2016−15−0201−00940). SAH was induced as described in detail before [16, 21]. Rats were
anesthetized using 3.5–4% Isoflurane (Baxter, Illinois, USA) in atmospheric air/O2 (70%/30%).
Rats were orally intubated and ventilated (Volume controlled ventilator, UGO Basile, Italy)
with 1.5–2% Isoflurane in N2O/O2 (70%/30%) during surgery. Blood samples were regularly
obtained with capillary tubes and analysed in a blood gas analyser (ABL80 FLEX, Radiometer,
Denmark). Body temperature was kept at 37.5 ± 0.5˚C using a regulated heating pad (TC-
1000, CWE, Inc., PA, USA). Mean arterial blood pressure (MABP) and ICP were continuously
measured by catheters inserted into the tail artery and the cisterna magna, respectively con-
nected to pressure transducers and a Powerlab unit and recorded by the LabChart software (all
from AD Instruments, Oxford, UK).
A laser- doppler blood flow meter probe (Oxford Optronix, UK) was placed on the dura
through a hole in the skull drilled 4 mm anterior from bregma and 3 mm to the right of the
midline. Through a second hole drilled 6,5 mm anterior to bregma on the midline, a 25G Spi-
nocan cannula (REF:4505905, B. Braun Melsungen AG, Germany) was lowered stereotactically
at an angle of 30˚ to the vertical plane towards a final position of the tip, immediately anterior
to the chiasma opticum. Lidocaine: adrenaline 10 mg/mL: 5 μg/mL (Amgros, Denmark) was
injected subcutaneously in the areas of incision.
After 15 minutes of equilibration, 300 μL of blood was withdrawn from the tail catheter and
injected manually through the cannula. The pressure and rate of the blood injections was man-
ually controlled aiming at raising ICP above the mean MABP levels in all animals. All rats,
except for rats in the sham group, were subjected to the full procedure. Sham operated rats
went through the same procedure, with the injection of blood intracisternally being omitted.
Rats were further maintained under anaesthesia for another 30 minutes while continually
recording ICP and CBF (sample trace in S1 Fig). After an additional 15 minutes, surgical
equipment was removed from the rat, its incisions were closed, followed by extubation and
recovery.
At the end of the procedure, a PinPort (PNP3F22, Instech, US) was placed at the end of
the ICP catheter, for later access for the injectable treatments by a PinPort injector (PNP-
3M, Instech, US). At the end of the procedure and after 24 hours, the rats received subcuta-
neous injections of Carprofen (Norodyl, 5 mg/kg) (Scanvet, Denmark). It has been demon-
strated that this dose of Carprofen does not prevent SAH-induced vascular inflammation
[17, 18].
Treatment regimens
The rats were briefly put under anaesthesia with isoflurane 3.5–4% (maintained at 1.75–2%) in
atmospheric air/O2 (70%/30%) using a facemask and given 5 mL isotonic saline subcutane-
ously in conjunction with each treatment for hydration, except for; 7.5 mL isotonic saline for
the single (6h treatment) high dose U0126 group and 5 mL isotonic saline in conjunction with
the post procedure carprofen treatment for the subcutaneous (s.c.) nimodipine group. The
intrathecal (i.t.) administrations were given through PINPORT via the ICP catheter placed in
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the cisterna magna during the operational procedure. The detailed treatment regimens can all
be found in Table 1.
Choice of doses. U0126 is yet to be tested in human subjects. Therefore, the current con-
centration and dose of U0126 used, is based on previous in vivo and ex vivo studies [22–24].
The treatment group receiving a single high dose of U0126 was only i.t. treated 6 hours post-
SAH, whereas the other U0126 i.t. treatments were given at 6, 12 and 24 hours after the experi-
mental SAH.
For the i.t. nimodipine dose, we selected the same time points as for U0126. For the dose of
i.t. nimodipine, Ha¨nggi et al [25] used 1μg/hour (low) or 2 μg/hour (high) dose of nimodipine,
with the low dose being the most efficient. We decided to give the rats 3 doses of 1.1 μg within
18 hours, where one 1.1 μg dose diluted in 90 μL [26] CSF will equal 11.1 μg/mL (25 μM). In
humans an intracranial dose of 400 μg/hour has been applied, which theoretically will give an
initial concentration of 3.2μg/mL (7 μM) [27]. Furthermore, the peak nimodipine concentra-
tion in the CSF of dogs was 3 μg/mL (7 μM) after 100 mg slow release nimodipine polymer
[28].
For the s.c. nimodipine we applied a dose similar to other studies [29–31]. Calle et al, mea-
sured 31–42 ng/mL in plasma, 12 hours after 4 mg/mL [29], which parallels a human study
where clinically relevant intravenous (i.v.) injections of 2.0 mg/hour gave a steady-state nimo-
dipine concentration of 27.1–34.0 ng/mL [32]. 2.5 mg/kg s.c. nimodipine has been shown to
be better than oral treatment of SAH in rabbits, and we chose this experimental approach [30].
Comparing the current treatment (here therefore exemplified with s.c. nimodipine given after
6 and 24 hours the experimental SAH), we did not include a vehicle. This will allow us to com-
pare the treatments, but not the absolute treatment effect of s.c. nimodipine similar to the
NEWTON-2 study, which compares enteral nimodipine with a slow release nimodipine poly-
mer [33].
All i.t. treatments were dissolved in 0.5% cremophor EL (Kolliphor EL) in Elliott’s B (artifi-
cial cerebrospinal fluid): NaCl 125 mM, NaHCO3 23 mM, dextrose 4 mM, MgSO4 1 mM, KCl
4 mM, CaCl2,1 mM and Na2HPO4 1 mM.
Neurological function—Rotating pole test
Gross sensorimotor function was evaluated using a rotating pole test [34]. This method evalu-
ates the ability of the animals to balance and to integrate and coordinate their movements to
Table 1. Treatment regimens.
Groups Concentration Drug administration Dose volume
(μL)
Single Dose
(μg)
Total dose/Mean weight
(μg/kg)�
Sham - - - - -
SAH - - - - -
Vehicle 0.5% CremophorEL (38 mM) in Elliotts B
(artificial cerebrospinal fluid)
i.t. (6h, 12h & 24h) 15 77.25 710.9
High dose U0126 10 μM in vehicle i.t. (6h, 12h & 24h) 15 0.064 0.589
Single high dose U0126 10 μM in vehicle i.t. (6h) 15 0.064 0.196
Low dose U0126 1 μM in vehicle i.t. (6h, 12h & 24h) 15 0.006 0.059
I.t. Nimodipine 175 μM in vehicle i.t. (6h, 12h & 24h) 15 1.098 10.11
S.c. Nimodipine 478 μM; Per mL: in
150 mg ethanol,
150 polyethylene glycol, 2.3 mg sodium citrate
s.c. (6h & 24h) 8000 1600 9816
�Mean animal weight of 326 g used.
https://doi.org/10.1371/journal.pone.0215398.t001
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traverse a horizontal pole rotating at 10 rpm. At one end of the pole (45 mm in diameter and
150 cm in length) a cage was placed with an entrance hole facing the pole. The floor of the cage
was covered with bedding material and some food from the home cage of the rat being tested,
thus serving as positive reinforcement for the rat to traverse the pole, when placed at the end
furthest from the cage. Rat performance was scored according to the following definitions:
Low, the animal is unable to cross the pole without falling off; High, the animal can traverse
the entire pole without falling off. Before surgery all animals were trained to traverse the pole.
On day 1 and 2 after surgery, each animal was scored twice for left and right rotation respec-
tively, i.e. 4 counts per animal. Animals were graded by personnel blinded to the experimental
groups of the animals. The behavioural evaluations are directly comparable to the myograph
data (same animals used) but that is not the case for the flow cytometry (S1 Fig).
Harvest of cerebral arteries
Rats were sedated with O2/CO2 (30/70%) and sacrificed by decapitation 48 hours after the
experimental SAH had been induced. Brains were removed quickly and chilled in cold oxygen-
ated buffer solution of the following composition: 119 mM NaCl, 4.6 mM KCl, 1.5 mM CaCl2,
1.2 mM MgCl2, 1.2 mM NaH2PO4, 15 mM NaHCO3 and 5.5 mM glucose; pH 7.4. Middle
cerebral arteries (MCAs), basilar arteries (BAs) and the circle of Willis (CW) were carefully
dissected from the brains and put in buffer solution for further investigations.
Myograph–ex vivo pharmacology
For contractility measurements, the MCAs were cut into cylindrical artery segments and
mounted in a wire myograph. The segments were equilibrated in the above buffer solution and
the wires separated for isometric pretension at 2 mN/mm. An absolute cut-off was set at 0.8
mN for K+ responses for inclusion of MCA arterial segments in the study.
K+ responses were performed by exchanging the buffer with a 60 mM K+ buffer solution. To
maintain equal osmolarity, a proportional amount of Na+ had been removed from the buffer.
Endothelium function was evaluated with the addition of 5-hydroxytryptamine (5-HT, 3x10-7
M) followed by carbachol (10−5 M). Cumulative concentration-response curves were performed
for endothelin-1 (ET-1) (10−14–10−7 M). Subsequent to the ET-1 precontracted arteries (10−7
M), nimodipine was added (10−7 M) and a concentration-response curve to Ca2+ (0.0125–3
mM) was performed. The Ca2+ curves were performed by adding increasing volumes of CaCl2,
from a 125 mM stock solution, to a Ca2+ free buffer solution. Ca2+ free buffer solution had simi-
lar composition as the buffer above, but 1.5 mM CaCl2 was exchanged with 0.03 mM EDTA.
Single cell isolation and intracellular flow-cytometry
Intracellular flow-cytometry was performed to investigate the protein expression of ETB, tran-
sient receptor potential cation channel subfamily C member 6 (TRPC6), matrix metalloprotei-
nases (MMP2 and MMP9) in VSMCs within cerebral vessels (BA, MCA and CW). Detailed
method is described elsewhere [35]. Briefly, VSMCs from segments of MCAs, BAs and CW
not used for myography, were isolated by enzymatic digestion with 1.25 mg/mL of highly puri-
fied Collagenase I and Collagenase II in a medium of Thermolysin. Dead cells were labelled
irreversibly by Fixable Viability Dye eFluor 780 with 1 μL to a concentration of 1-10x106 cells/
mL, prior to the fixation and permeabilization.
The cell suspensions were stained with primary antibodies; goat anti-SM22α (1:100;
ab10135; 0,5 mg/mL, Abcam, UK), rabbit anti-ETB (1:100; ab117529; Whole serum, Abcam,
UK), rabbit anti-TRPC6 (1:100; acc-120; 0.85 mg/mL, Alomone), rabbit anti-MMP9 (1:100;
ab38898; 1 mg/mL, Abcam, UK), rabbit anti-MMP2 (1:100; ab37150; 1 mg/mL, Abcam, UK),
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goat isotope control IgG (5 μg/mL; ab18433; 5 mg/mL, Abcam, UK) or rabbit isotope control
IgG (8.5/10 μg/mL; ab37416; 5 mg/mL, Abcam, UK) in blocking buffer and subsequently with
secondary antibodies; Alexa 488-conjugated donkey anti-goat IgG (1:500; A-11055; 2 mg/mL,
Life Technologies) or Allophycocyanin (APC)-conjugated donkey anti-rabbit IgG (1:100; 711-
136-152; 0.5 mg/mL, Jackson Immuno Research). The analyses by fluorescent-activated cell
sorting (FACS) were performed on a BD FACSVerse machine (BD Biosciences, USA), by exci-
tation with a blue laser at 488 nm and a red laser at 640 nm, using the BD FACSuite Software.
The ratio of SM22α-positive viable cells expressing TRPC6, ETB, MMP2 or MMP9 was then
calculated for each sample. This assay included 7 additional rats of similar weights (fresh), not
having undergone the experimental SAH or sham procedure, which allows us to establish a
true naïve baseline. The variable number of n in some subsets for the flow cytometry is due to
unsatisfactory sample cell count.
Reagents and statistics
Endothelin-1 was purchased from Polypeptide (Sweden), while other chemicals such as U0126
(U120), nimodipine (PHR1293) and cremophor (C5135), were obtained from Sigma Aldrich
(Germany).
Contractility data is shown as percentage of the 60 mM K+max plateau from Ca
2+ free base-
line. Each n for the cumulative ET-1 concentration response curves and ET-1 pre-contracted
cumulative [Ca2+] response curves is depicted as mean per animal (1–2 vessels per n). When
the artery reached maximum contraction before the last concentration was added, the curves
were constrained to the maximum contraction. All quantitative data are presented as
mean ± SEM, showing how precisely we have determined the true mean.
The difference between two concentration response curves was determined by two-way
repeated measures ANOVA followed by Bonferroni post-test between two groups. The differ-
ence in a single variable between multiple groups was compared by using a one-way ANOVA
followed by Bonferroni post-test between all groups. The difference in neurological function
between groups was determined by two-tailed Fischer’s exact test. The difference in protein
expression between groups was determined by using a one-way ANOVA followed by Bonfer-
roni post-test between two groups. Statistical analyses were done using Graphpad software and
significant p-values were defined as: � = p< 0.05, �� = p< 0.01, ��� = p< 0.001.
Results
Experimental SAH surgery data
The surgery data from the rats were carefully observed and recorded, the MABP (83.59 ± 1.5
mmHg), pH (7.40 ± 0.01), pCO2 (5.70 ± 0.63 kPa), pO2 (16.85 ± 0.32 kPa), ICP (140.4 ± 3.1
mmHg) and temperature were within acceptable physiologic limits during surgery (S1 Table).
Middle cerebral artery function
Contractile responses (mN) to 60 mM K+, including vessels under the cut-off, showed a signif-
icant difference between the groups by one-way ANOVA (p = 0.0377), but not by Bonferroni
post-test. This show a tendency of the single high dose U0126 group being lower than the
other groups (Fig 1A). The individual vessel lengths (range 1–1.7 mm; 1.37 ± 0.01), were not
significantly different between the groups (Fig 1B). Contractile responses to 60 mM K+ (mN/
mm), only including vessel over the cut-off as mean per animal (1–2 vessels per n), showed no
significant difference between the groups (Fig 1C). For the same vessels, there were no differ-
ences in the endothelium dependent responses to carbachol (Fig 1D).
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Effect of U0126 and nimodipine treatment on contractile responses to ET-1
In this study we compared U1026 with nimodipine, a dihydropyridine calcium channel
blocker currently used as standard treatment for SAH [9, 10], by cumulative ET-1 concentra-
tion-response curves (10−14–10−7 M) with five different U0126 or nimodipine treatment regi-
mens (Table 1). This included a single high dose (6 hours after induced SAH), a low dose of
Fig 1. K+max, vessel lengths and endothelium responses after U0126 and nimodipine treatments. The figure shows wire-myography of middle cerebral arteries
(MCAs) performed at isometric tension. (A) K+max (mN) in response to 60 mM K
+ adjusted to Ca2+ free baseline and including all vessels and (B) vessel lengths
(mm), for sham (n = 10), SAH (n = 12), vehicle (n = 12), high dose U0126 (n = 12), single high dose U0126 (n = 14), low dose U0126 (n = 12), i.t. nimodipine (n = 11)
and s.c. nimodipine (n = 10) groups. (C) K+max (mN/mm) in response to 60 mM K
+ adjusted to Ca2+ free baseline. (D) Endothelium responses (%) evaluated with
5-HT (3x10-7 M) and Carbachol (10−5 M). Data for C and D are presented as mean per animal (1–2 vessels per n), excluding vessels under 0.8 mN cut-off, for sham
(n = 5), SAH (n = 6), vehicle (n = 6), 10 μM U0126 (n = 6), solo dose 10 μM U0126 (n = 7), 1 μM U0126 (n = 6), i.t. nimodipine (n = 6) and s.c. nimodipine (n = 5)
groups. All animals, excluding sham group animals, were exposed to experimental SAH. Horizontal dotted black lines show Totalmean of all n and horizontal dotted
red line shows 0.8 mN cut-off for Kmax contractility. Data shown as mean ± SEM, with statistics by one-way ANOVA with Bonferroni post-test and with significance
shown as � = p<0.05; �� = p< 0.01; ��� = p< 0.001.
https://doi.org/10.1371/journal.pone.0215398.g001
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U0126 and a high dose U0126. The high dose treatment regimen was previously used in other
studies [14, 15]. In addition to an i.t. treatment of nimodipine, a systemic treatment of s.c.
nimodipine was also studied (Table 1).
The ET-1 concentration-response curves showed lower ET-1max contractions for the high
dose U0126 (154 ± 8%) group compared to the vehicle (211 ± 21%) group (Fig 2A), while the
single high dose U0126 group (270 ± 30%) showed higher ET-1max contractions than the high
dose U0126 group (154 ± 8%). The low dose U0126 group (211 ± 27%) showed no significant
differences from any of the other groups (Fig 2B). The s.c. nimodipine group (230 ± 24%) and
i.t. nimodipine group (254 ± 39%) both showed higher ET-1max contractions when compared
to the high dose U0126 group (154 ± 8%) (Fig 2C). The single high dose U0126, i.t. nimodipine
and SAH group curves showed increased sensitivity to ET-1 compared to the high dose U0126
group, while the single high dose U0126 group showed a higher sensitivity when compared to
the vehicle group (Fig 2). In addition, a competitive curve fit was performed comparing
biphasic vs. variable slope regression. The results show that the following groups had a biphasic
best curve fit: SAH, single high dose U0126, low dose U0126 and both i.t./s.c. nimodipine. In
contrast, the sham, vehicle and high dose U0126 groups had a variable slope as the best fit. In
addition to the best fit values, the ET-1max and EC50 values can also be found in Table 2.
Effect of U0126 and nimodipine treatments on neurologic function
To evaluate the rat deficits induced by experimental SAH and the effect of the different treat-
ments, rats were subjected to a rotating pole test post SAH. From 24 to 48 hours post SAH
(Data shown: (% high/total scored), only the rats treated with high dose U0126 (Score24h 67%
to Score48h 100%) or low dose U0126 (Score24h 63% to Score48h 96%) demonstrated neurologi-
cal score improvements (Fig 3).
At 48 hours (data shown: % high scored/total scored), the rats in the i.t. nimodipine (58%)
group had a lower neurological score than the animals treated with s.c. nimodipine (90%),
high dose U0126 (100%) and vehicle (88%) (Fig 4). Importantly, only the rats treated with low
dose U0126 (96%) and high dose U0126 (100%) managed to score significantly better than
SAH animals (67%). In addition, there was a significant difference between SAH (67%) and
sham (100%) (Fig 4B). See S2 Table for all score percentages.
Nimodipine dependent desensitization after prolonged treatment
To investigate if the prolonged nimodipine treatments resulted in increased contractility by
nimodipine insensitive voltage-dependent calcium channels (VDCCs), we performed ET-1
pre-contracted cumulative Ca2+ concentration-response curves (0.0125–3 mM) in the pres-
ence of 10−7 M nimodipine, a concentration similar to other studies [36]. There were no signif-
icant differences between the sham, SAH and vehicle groups compared to the U0126 groups
(Fig 5A), but the i.t. nimodipine treatment (8.3 ± 2.3%) and s.c. nimodipine treatment
(6.3 ± 1.2%) groups showed higher ET-1max contractions than the high dose U0126
(3.3 ± 0.7%) treatment group (Fig 5B).
U0126 and nimodipine related alterations to protein expression
To elucidate why the contractility was even higher in the nimodipine groups, we investigated
if the 48 hours nimodipine treatments resulted in increased expression of TRPC6 which has
been shown to be important in other models of ischemia [36]. In addition, we wanted to vali-
date the ETB receptor expression [16] and investigate VSMC-related loss of blood-brain bar-
rier integrity associated with SAH. Analyses were performed by intracellular flow-cytometry
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and the protein expression were quantitatively measured on viable VSMCs, isolated from cere-
bral vessels, with focus on the following proteins; ETB, TRPC6, MMP9 or MMP2.
The percentage of VSMCs expressing ETB receptor protein was significantly higher in the
vehicle group (61 ± 9%), when compared to the rats treated with high dose U0126 (30 ± 4%)
and the fresh group (36 ± 5%) (Fig 6A). There was also a tendency of a higher percentage of
VSMCs expressing TRPC6 following the treatment with i.t. nimodipine (12.7 ± 2.5%), when
compared to the fresh and vehicle groups (6.8 ± 1.8; 7.0 ± 1.9%) (Fig 6B). The percentage of
VSMCs expressing MMP2 was significantly higher in the vehicle (53 ± 6%) and U0126 group
(51 ± 10%) compared to the fresh group (23 ± 9%), with a tendency of being higher in the i.t.
nimodipine groups (45 ± 6%) compared to the fresh group (Fig 6C). The percentage of
VSMCs expressing MMP9 was significantly higher in the vehicle group (53 ± 3%) compared
to the fresh group (28 ± 6%), but not when comparing the U0126 (42 ± 8%) and i.t. nimodi-
pine groups (42 ± 9%) to the fresh group (Fig 6D).
Discussion
The present study is the first to show that high dose U0126 is superior treatment to nimodipine
for experimentally induced SAH in rats, when evaluated by vessel contractility, neurological
outcome and expression of selected proteins. The current established drug treatment for DCI,
nimodipine, improved rat outcome but only when given subcutaneously. The results are dis-
cussed regarding treatment regimens and the current medical guidelines from the European
and American stroke associations [9, 10].
U0126 treatment regimens
We initially set out to determine the optimal treatment regimen, as previous research had not
fully evaluated dose and treatment frequency versus effects in vivo. Both the high and the low
Fig 2. Cumulative ET-1 concentration-response curves after U0126 and nimodipine treatments. ET-1 contractions
were normalized to K+max contractions (60 mM) adjusted to Ca
2+ free baseline of middle cerebral arteries (MCAs),
performed with wire-myograph at isometric tension. Cumulative ET-1 concentration response curves (10−14–10−7 M)
of MCAs for (A-C) sham (n = 5), SAH (n = 6), vehicle (n = 6) and high dose U0126 (n = 6) groups. (B) Single high
dose 10 μM U0126 (n = 7) and low dose U0126 (n = 6) groups. (C) I.t. nimodipine (n = 6) and s.c. nimodipine (n = 5)
groups. All animals, excluding sham group animals, were exposed to experimental SAH. The same data from sham,
SAH, vehicle and high dose U0126 groups were used in Fig 2A, Fig 2B, and Fig 2C. Data is given as mean per animal
(1–2 vessels per n) ± SEM, with statistics by two-way ANOVA with Bonferroni post-test and significant difference
between two curves shown as �/$/§/&/@ = p< 0.05; ��/$ $/§§/&&/@@ = p< 0.01; ���/$ $ $/§§§/&&&/@@@ =
p< 0.001. Nonlinear curve fits by competition between biphasic and log[agonist] vs. response with variable slope,
weighted for mean Y at each point.
https://doi.org/10.1371/journal.pone.0215398.g002
Table 2. Endothelin-1max and curve fits.
Groups ET-1max
(% of K+max)
Curve fit competition
biphasic versus log(agonist) vs. response—variable slope
Biphasic p-values High sensitivity ± SEM Low sensitivity ± SEM
Sham 194 ± 22 log(agonist) vs. response—variable slope - -9.403 ± 0.047
SAH 200 ± 34 < 0.0001 -11.020 ± 0.254 -9.352 ± 0.025
Vehicle 211 ± 21 log(agonist) vs. response—variable slope - -9.035 ± 0.038
High dose U0126 154 ± 8 log(agonist) vs. response—variable slope - -9.240 ± 0.047
Single high dose U0126 270 ± 30 0.0002 -11.130 ± 1.350 -9.188 ± 0.039
Low dose U0126 211 ± 27 0.0037 -10.630 ± 2.318 -8.918 ± 0.100
I.t. Nimodipine 253 ± 39 0.0003 -10.590 ± 1.288 -9.258 ± 0.055
S.c. Nimodipine 230 ± 24 0.003 -9.322 ± 0.206 -8.719 ± 0.066
https://doi.org/10.1371/journal.pone.0215398.t002
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doses of U0126 improved neurological outcome (Fig 3), while the high dose U0126 group
showed a significant suppressive effect on ET-1max and a lower sensitivity to ET-1 (Fig 2). This
indicates that MCAs from rats treated with high dose U0126 has lower ET-1 contractility com-
pared to vehicle and untreated animals, which we hypothesize is important for long term out-
come, as evaluated in previous studies [16].
The endothelin receptor was used as a sensitive marker for contractility changes, since we
have before observed that this change also is seen for other cerebrovascular contractile recep-
tors after SAH [37]. The use of an ETA/ETB receptor blocker such as clazosentan was only seen
Fig 3. Behavioural evaluation of U0126 treatment by rotating pole test. Rotating pole test at 10 rpm for sham (n = 5), SAH
(n = 6), vehicle (n = 6), high dose U0126 (n = 6), single high dose U0126 (n = 7) and low dose U0126 (n = 6) groups, at (A) 24
hours post experimental SAH and (B) 48 hours after experimental SAH. Scored with 4 counts per animal, i.e. 2 scores for left-
and right rotation respectively; Low = unable to cross in one try; High = able to cross in one try. The high dose U0126(�) and
low dose U0126(�) groups had significant improvements in score from 24 hours to 48 hours. The same data from sham, SAH,
vehicle and high dose U0126 groups were used in Fig 3. and Fig 4. All animals, excluding sham group animals, were exposed
to experimental SAH. Statistics done by Fischer’s exact test, two-sided, 95% CI. Significance shown as � = p< 0.05); �� =
p< 0.01; ��� = p< 0.001.
https://doi.org/10.1371/journal.pone.0215398.g003
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to have a partial effect. Targeting the transcriptional events following SAH with a MEK1/2
antagonist is the best way to downregulate all the contractile receptors [16].
After determining the optimal dose, we also investigated whether a single high dose of
U0126 i.t. injection at 6 hours, compared to three injections at 6, 12 and 24 hours, could be
efficient in treating experimental SAH in rats. In the single high dose U0126 group we found a
tendency of a low K+ response in the MCAs (Fig 1A and 1D). This could indicate an undesir-
able effect on the VSMC membrane potential, possibly due to an effect on receptors or ion
channels involved in the handling of cations. Furthermore, the results obtained from the single
Fig 4. Behavioural evaluation of nimodipine treatment by rotating pole test. Rotating pole test at 10 rpm at for sham (n = 5), SAH
(n = 6), vehicle (n = 6), high dose U0126 (n = 6), i.t. nimodipine (n = 6) and s.c. nimodipine (n = 5) groups, after (A) 24 hours post
experimental SAH and (B) 48 hours post experimental SAH. Scored 4 counts per animal, i.e. 2 scores for left- and right rotation
respectively; Low score = unable to cross in one try; High score = able to cross in one try. The same data from sham, SAH, vehicle
and high dose U0126 groups were used in Fig 3. and Fig 4. All animals, excluding sham group animals, were exposed to experimental
SAH. Statistics done by Fischer’s exact test, two-sided, 95% CI. Significance shown as � = p< 0.05; �� = p< 0.01; ��� = p<0.001.
https://doi.org/10.1371/journal.pone.0215398.g004
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treatment group might be explained by phenotypic modulation of VSMCs [20]. The contrac-
tions in response to ET-1 was higher after the single treatment compared to the triple high
dose U0126 treatment (Fig 2B). Combined with the lack of neurological improvement in SAH,
a single dose cannot be recommended. We therefore conclude that the triple treatment regi-
men with high dose U0126, is the optimal dose and procedure for treatment. The use of high
dose U0126 treatment in our study is consistent with previous ex vivo studies [22, 23] and in
vivo studies [16, 24].
Cremophor EL
Previous studies applying U0126 in i.t. treatment has used DMSO as solvent for the weakly
polar U0126 [16, 18, 24]. A more relevant vehicle for human application is cremophor EL,
which is a synthetic non-ionic surfactant used to stabilize emulsions of nonpolar materials in
water, that has been used as a vehicle in clinical trials [38]. Although it was originally thought
to be an inert vehicle, this might not be the complete story. Cremophor EL has been shown to
modify pharmacokinetic properties of other compounds [38, 39] and to specifically inhibit
protein kinase C (PKC) activity [40]. Relevant to the current study, PKC inhibition has been
shown to attenuate ETB receptor upregulation ex vivo [41] and in vivo in SAH [42]. In our
study, cremophor (vehicle) had some effect on the ETB upregulation, but it was not completely
attenuated (Fig 6). In addition, we did observe a lower sensitivity to ET-1 (Fig 2) and a better
neurological outcome for the vehicle group compared to the SAH group (Fig 3).
We postulate that there is a positive effect of the vehicle used in this study, which might
have some implication when interpreting differences between vehicle and the compounds
Fig 5. Cumulative [Ca2+] response curves precontracted with ET-1 after U0126 and nimodipine treatments. Ca2+ dependent ET-1 contractions were normalized to
K+max (60 mM) contractions adjusted to Ca
2+ free baseline of middle cerebral arteries (MCAs), performed with wire-myograph at isometric tension. ET-1
precontracted (10−7 M) cumulative [Ca2+] response curves (0.0125–3 mM) of MCAs for (A) sham (n = 5), SAH (n = 6) and vehicle (n = 6). (A-B) High dose U0126
(n = 6) (B) I.t. nimodipine (n = 6) and s.c. nimodipine (n = 5) groups. The same data from high dose U0126 groups were used in Fig 5A and Fig 5B. All animals were
exposed to experimental SAH. Each n per animal is composed of 1–2 vessel n. Data shown as mean ± SEM with statistics by two-way ANOVA with Bonferroni post-
test and significant difference between two curves shown as �/# = p< 0.05 ��/## = p< 0.01; ���/### = p< 0.001.
https://doi.org/10.1371/journal.pone.0215398.g005
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tested. In SAH, blood and blood breakdown products have been shown to contribute to DCI
[3, 43, 44]. In addition to the possible effect on PKC, the i.t. administration itself could also
have an effect since a local injection of a synthetic non-ionic surfactant might affect the
Fig 6. Intracellular flow cytometry of VSMCs derived from digested cerebral vessels. Intracellular flow cytometry was performed to investigate the protein
expression of A) ETB, (B) TRPC6, (C) MMP2 and (D) MMP9 in vascular smooth muscle cells (VSMCs), obtained from cerebral vessels (basilar artery, middle cerebral
artery and circle of Willis), from fresh (n = 4–7), vehicle (n = 5–6), high dose U0126 (n = 4–7) and i.t. nimodipine (n = 5–6) groups. All animals, excluding the fresh
group animals, were exposed to experimental SAH. Data are shown as mean ± SEM with statistics by one-way ANOVA with Bonferroni post-test and with significance
shown as � = p< 0.05; �� = p< 0.01; ��� = p< 0.001.
https://doi.org/10.1371/journal.pone.0215398.g006
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clearance of the blood in the subarachnoid space. This would be less relevant with systemic
drug administration, i.v. or intraperitoneal (i.p.), where the solvent is diluted to a level that has
low efficacy per se. An effect on PKC activity and disruption of the blood clot in the subarach-
noid space could explain some of the positive effects of vehicle in the current experimental
SAH study.
Ca2+ curves
We did not observe any effect of nimodipine treatment on the contractility following depolari-
zation after 60 mM K+ (Fig 1). By itself, it shows that the direct effect of nimodipine is not pres-
ent 24 hours after final treatment. Although the contraction to a depolarizing stimulus was not
affected, we hypothesized, that nimodipine treatment could affect the relation between volt-
age-dependent calcium channels (VDCC) and voltage insensitive channels, such as store oper-
ated calcium channels (SOCC). We have previously shown that calcium handling is affected
following different kinds of experimental ischemia, such as global cerebral ischemia [36] and
heart ischemia [45]. The differences in ET-1max in the presence of nimodipine shown in Fig 5,
indicate a general increased contraction in MCAs from rats treated with nimodipine com-
pared to high dose U0126 treatment. Hence, the high dose U0126 and nimodipine treatments
have opposite effects on the nimodipine insensitive contractions.
The results obtained from the Ca2+ curves suggest that the two nimodipine treatment regi-
mens result in larger nimodipine-insensitive contractions after just a short treatment period of 48
hours. These effects could be exacerbated in patients treated with an oral treatment given every 4
hours for 3 weeks, as recommended by the European Stroke Guidelines to prevent delayed ische-
mic deficits in SAH patients [10]. We observed higher nimodipine insensitive Ca2+ contractions
in MCAs from rats treated with either of the nimodipine regimens compared to vehicle (Fig 5),
but despite the similarity in the nimodipine insensitive Ca2+ contractions, we observed improved
outcome only after the s.c. nimodipine treatment. We postulate that this could be related to the
higher ET-1 sensitivity and ET-1max after i.t. nimodipine treatment (Fig 2).
In a rabbit SAH model it has been shown that s.c. nimodipine is superior to oral nimodi-
pine [30], validating our current approach. The differences seen in this study between the two
nimodipine treatments is most likely related to the route of drug administration. In the Euro-
pean guidelines, oral administration of nimodipine is deemed preferable to i.v. treatment [10],
and human i.v. treatment with nimodipine is unavailable in North America [46]. Hence, our
study does not challenge the current clinical guidelines for nimodipine.
I.t. nimodipine did not show improved outcome over s.c. nimodipine in our study. The
most current clinical work has been focused on applying a nimodipine containing biodegrad-
able polymer suspended in hyaluronic acid (EG-1962), which after intraventricular injection
slowly releases nimodipine into the subarachnoid space for at least 21 days [47]. The phase 1/2A
clinical study showed good effects on DCI [33]. However, the most recent phase 3 clinical trial
involving EG-1962, which compared the intracranially delivered nimodipine product EG-1962
to oral nimodipine was terminated (25th of July 2018) due to a low probability of the study
meeting its primary outcome measure. The primary outcome measure was defined as “Propor-
tion of subjects with a favourable outcome measured on the Extended Glasgow Outcome Scale
(GOSE) at Day 90”, compared to enteral (oral) nimodipine treatment (NCT02790632). There
were no vehicle arms in any of these studies.
Protein expression
We have previously shown that SAH induces changes in cerebrovascular protein expression.
We confirmed the increased protein expression of ETB receptor protein in VSMCs after SAH
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and the inhibition by U0126 treatment is consistent with previous data [37], indicating similar
effects on the protein expression profile for DMSO and cremophor. We here applied samples
from naïve rats, to compare the treatments to an absolute baseline.
Nimodipine did not significantly reduce the expression of ETB receptor. In addition to ETB
upregulation, we observed a tendency of more VMSCs in the i.t. nimodipine treatment group
expressing TRPC6 receptors, when compared to the fresh (naïve baseline) and vehicle groups.
The increased expression of TRPC6 receptors offer a possible explanation for both the
increased contractions to ET-1 and the nimodipine-insensitive contractions following nimodi-
pine treatment. Additional long-term studies are needed to make final conclusions.
MMP9 and MMP2 were more expressed by VSMCs in the vehicle group. We cannot con-
clude by our results whether U0126 or nimodipine reduced the MMP9 expression (Fig 6D).
This is in contrasts to another study where MMP9 expression was significantly reduced in
MCAs from rats subjected to middle cerebral artery occlusion (MCAO), another model of
cerebral ischemia, and treated with U0126 [48]. However, it is important to recognize that
with flow cytometry analysis we measured protein expression above a threshold, in individual
cells (gated using a VSMC marker) and not the absolute expression in mixed tissue. In addi-
tion, there might be general model differences between SAH and MCAO.
Clinical perspectives and conclusion
In this study we conclude that the most desirable treatment regimen for vascular phenotypic
modulation and outcome following experimental SAH (which we believe is an important con-
tributor to DCI), is three administrations (6 h, 12 h and 24 h) of high (10 μM, 0.064 mg/kg)
dose U0126. This conclusion is mainly drawn by showing improved neurological outcome
and lower contractility to ET-1 in the high dose U0126 group compared to the nimodipine
treatment groups and untreated SAH group. Both the low dose and high dose U0126 treat-
ments improved outcome, unlike treatment with a single high dose of U0126 at 6 hours after
induced SAH. In the myograph, only arteries from SAH rats treated with a high dose U0126
were significantly different from arteries isolated from untreated SAH rats. The current clinical
treatment with nimodipine, exemplified with s.c. nimodipine treatment, had improved out-
come, contrasting with the unbeneficial i.t. nimodipine treatment. Similarly, a clinical trial
involving a slow release intracranial nimodipine polymer was recently terminated, as it was
unlikely to meet the primary outcome measure of being more efficient than enteral nimodi-
pine. Our results support that U0126 is a viable treatment for SAH, and a possible clinical
study would be of high interest.
Supporting information
S1 Dataset.
(XLSX)
S1 Fig.
(TIF)
S1 Table. Experimental subarachnoid haemorrhage parameters.
(XLSX)
S2 Table. Vessel parameters and rotating pole score percentages.
(XLSX)
U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after SAH
PLOS ONE | https://doi.org/10.1371/journal.pone.0215398 April 12, 2019 16 / 20
Author Contributions
Conceptualization: Simon T. Christensen, Sara E. Johansson, Karin Warfvinge, Lars
Edvinsson.
Data curation: Simon T. Christensen, Sara E. Johansson, Aneta Radziwon-Balicka, Kristian A.
Haanes.
Formal analysis: Simon T. Christensen, Aneta Radziwon-Balicka, Kristian A. Haanes.
Funding acquisition: Lars Edvinsson.
Investigation: Simon T. Christensen, Sara E. Johansson, Aneta Radziwon-Balicka, Kristian A.
Haanes.
Methodology: Simon T. Christensen, Sara E. Johansson, Aneta Radziwon-Balicka, Kristian A.
Haanes, Lars Edvinsson.
Project administration: Simon T. Christensen, Sara E. Johansson, Karin Warfvinge, Kristian
A. Haanes, Lars Edvinsson.
Resources: Lars Edvinsson.
Supervision: Sara E. Johansson, Karin Warfvinge, Kristian A. Haanes, Lars Edvinsson.
Visualization: Simon T. Christensen, Aneta Radziwon-Balicka, Kristian A. Haanes.
Writing – original draft: Simon T. Christensen, Kristian A. Haanes.
Writing – review & editing: Simon T. Christensen, Sara E. Johansson, Aneta Radziwon-
Balicka, Karin Warfvinge, Kristian A. Haanes, Lars Edvinsson.
References
1. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006; 354
(4):387–96. Epub 2006/01/27. https://doi.org/10.1056/NEJMra052732 PMID: 16436770.
2. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007; 369(9558):306–18. Epub
2007/01/30. https://doi.org/10.1016/S0140-6736(07)60153-6 PMID: 17258671.
3. Geraghty JR, Testai FD. Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Beyond Vaso-
spasm and Towards a Multifactorial Pathophysiology. Curr Atheroscler Rep. 2017; 19(12):50. Epub
2017/10/25. https://doi.org/10.1007/s11883-017-0690-x PMID: 29063300.
4. Lucke-Wold BP, Logsdon AF, Manoranjan B, Turner RC, McConnell E, Vates GE, et al. Aneurysmal
Subarachnoid Hemorrhage and Neuroinflammation: A Comprehensive Review. Int J Mol Sci. 2016; 17
(4):497. Epub 2016/04/07. https://doi.org/10.3390/ijms17040497 PMID: 27049383; PubMed Central
PMCID: PMCPMC4848953.
5. Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. J Cereb Blood
Flow Metab. 2016; 36(3):513–38. Epub 2015/12/15. https://doi.org/10.1177/0271678X15617172
PMID: 26661240; PubMed Central PMCID: PMCPMC4776312.
6. Findlay JM, Nisar J, Darsaut T. Cerebral Vasospasm: A Review. Can J Neurol Sci. 2015:1–18. Epub
2015/09/04. https://doi.org/10.1017/cjn.2015.288 PMID: 26332908.
7. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, et al. Calcium
antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;(3):
CD000277. Epub 2007/07/20. https://doi.org/10.1002/14651858.CD000277.pub3 PMID: 17636626.
8. Rinkel GJ. Management of patients with aneurysmal subarachnoid haemorrhage. Curr Opin Neurol.
2015. Epub 2015/12/08. https://doi.org/10.1097/wco.0000000000000282 PMID: 26641816.
9. Connolly ES Jr., Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines
for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals
from the American Heart Association/american Stroke Association. Stroke. 2012; 43(6):1711–37. Epub
2012/05/05. https://doi.org/10.1161/STR.0b013e3182587839 PMID: 22556195.
U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after SAH
PLOS ONE | https://doi.org/10.1371/journal.pone.0215398 April 12, 2019 17 / 20
10. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G. European Stroke Organization guide-
lines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis.
2013; 35(2):93–112. Epub 2013/02/15. https://doi.org/10.1159/000346087 PMID: 23406828.
11. Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD. Simvastatin in aneurysmal subarach-
noid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol. 2014; 13(7):666–
75. Epub 2014/05/20. https://doi.org/10.1016/S1474-4422(14)70084-5 PMID: 24837690.
12. Brathwaite S, Macdonald RL. Current management of delayed cerebral ischemia: update from results
of recent clinical trials. Transl Stroke Res. 2014; 5(2):207–26. Epub 2013/12/18. https://doi.org/10.
1007/s12975-013-0316-8 PMID: 24338266.
13. Laban KG, Vergouwen MD, Dijkhuizen RM, Sena ES, Macleod MR, Rinkel GJ, et al. Effect of endothelin
receptor antagonists on clinically relevant outcomes after experimental subarachnoid hemorrhage: a
systematic review and meta-analysis. J Cereb Blood Flow Metab. 2015; 35(7):1085–9. Epub 2015/05/
07. https://doi.org/10.1038/jcbfm.2015.89 PMID: 25944590.
14. Edvinsson LI, Povlsen GK. Vascular plasticity in cerebrovascular disorders. J Cereb Blood Flow Metab.
2011; 31(7):1554–71. Epub 2011/05/12. https://doi.org/10.1038/jcbfm.2011.70 PMID: 21559027;
PubMed Central PMCID: PMCPMC3137480.
15. Edvinsson L, Larsen SS, Maddahi A, Nielsen J. Plasticity of cerebrovascular smooth muscle cells after
subarachnoid hemorrhage. Transl Stroke Res. 2014; 5(3):365–76. Epub 2014/01/23. https://doi.org/10.
1007/s12975-014-0331-4 PMID: 24449486.
16. Povlsen GK, Edvinsson L. MEK1/2 inhibitor U0126 but not endothelin receptor antagonist clazosentan
reduces upregulation of cerebrovascular contractile receptors and delayed cerebral ischemia, and
improves outcome after subarachnoid hemorrhage in rats. J Cereb Blood Flow Metab. 2015; 35
(2):329–37. Epub 2014/11/20. https://doi.org/10.1038/jcbfm.2014.205 PMID: 25407271; PubMed Cen-
tral PMCID: PMCPMC4426751.
17. Maddahi A, Ansar S, Chen Q, Edvinsson L. Blockade of the MEK/ERK pathway with a raf inhibitor pre-
vents activation of pro-inflammatory mediators in cerebral arteries and reduction in cerebral blood flow
after subarachnoid hemorrhage in a rat model. J Cereb Blood Flow Metab. 2011; 31(1):144–54. Epub
2010/04/29. https://doi.org/10.1038/jcbfm.2010.62 PMID: 20424636; PubMed Central PMCID:
PMCPMC3049479.
18. Maddahi A, Povlsen GK, Edvinsson L. Regulation of enhanced cerebrovascular expression of proin-
flammatory mediators in experimental subarachnoid hemorrhage via the mitogen-activated protein
kinase kinase/extracellular signal-regulated kinase pathway. J Neuroinflammation. 2012; 9:274. Epub
2012/12/25. https://doi.org/10.1186/1742-2094-9-274 PMID: 23259581; PubMed Central PMCID:
PMCPMC3573995.
19. Rempe RG, Hartz AM, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: Versatile
breakers and makers. J Cereb Blood Flow Metab. 2016; 36(9):1481–507. Epub 2016/06/22. https://doi.
org/10.1177/0271678X16655551 PMID: 27323783; PubMed Central PMCID: PMCPMC5012524.
20. Frismantiene A, Philippova M, Erne P, Resink TJ. Smooth muscle cell-driven vascular diseases and
molecular mechanisms of VSMC plasticity. Cell Signal. 2018; 52:48–64. Epub 2018/09/02. https://doi.
org/10.1016/j.cellsig.2018.08.019 PMID: 30172025.
21. Prunell GF, Mathiesen T, Svendgaard NA. A new experimental model in rats for study of the pathophys-
iology of subarachnoid hemorrhage. Neuroreport. 2002; 13(18):2553–6. Epub 2002/12/25. https://doi.
org/10.1097/01.wnr.0000052320.62862.37 PMID: 12499866.
22. Henriksson M, Xu CB, Edvinsson L. Importance of ERK1/2 in upregulation of endothelin type B recep-
tors in cerebral arteries. Br J Pharmacol. 2004; 142(7):1155–61. Epub 2004/07/09. https://doi.org/10.
1038/sj.bjp.0705803 PMID: 15237095; PubMed Central PMCID: PMCPMC1575172.
23. Sandhu H, Ansar S, Edvinsson L. Comparison of MEK/ERK pathway inhibitors on the upregulation of
vascular G-protein coupled receptors in rat cerebral arteries. Eur J Pharmacol. 2010; 644(1–3):128–37.
Epub 2010/07/10. https://doi.org/10.1016/j.ejphar.2010.06.053 PMID: 20615400.
24. Larsen CC, Povlsen GK, Rasmussen MN, Edvinsson L. Improvement in neurological outcome and abo-
lition of cerebrovascular endothelin B and 5-hydroxytryptamine 1B receptor upregulation through mito-
gen-activated protein kinase kinase 1/2 inhibition after subarachnoid hemorrhage in rats. J Neurosurg.
2011; 114(4):1143–53. Epub 2010/07/06. https://doi.org/10.3171/2010.6.JNS1018 PMID: 20597604.
25. Hanggi D, Eicker S, Beseoglu K, Rapp M, Perrin J, Nawatny J, et al. Dose-related efficacy of a continu-
ous intracisternal nimodipine treatment on cerebral vasospasm in the rat double subarachnoid hemor-
rhage model. Neurosurgery. 2009; 64(6):1155–9; discussion 9–61. Epub 2009/06/03. https://doi.org/
10.1227/01.NEU.0000340685.06407.FD PMID: 19487896.
26. Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS. 2011; 8(1):7.
Epub 2011/02/26. https://doi.org/10.1186/2045-8118-8-7 PMID: 21349155; PubMed Central PMCID:
PMCPMC3042981.
U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after SAH
PLOS ONE | https://doi.org/10.1371/journal.pone.0215398 April 12, 2019 18 / 20
27. Hanggi D, Beseoglu K, Turowski B, Steiger HJ. Feasibility and safety of intrathecal nimodipine on post-
haemorrhagic cerebral vasospasm refractory to medical and endovascular therapy. Clin Neurol Neuro-
surg. 2008; 110(8):784–90. Epub 2008/06/17. https://doi.org/10.1016/j.clineuro.2008.05.001 PMID:
18554777.
28. Hanggi D, Etminan N, Steiger HJ, Johnson M, Peet MM, Tice T, et al. A Site-Specific, Sustained-
Release Drug Delivery System for Aneurysmal Subarachnoid Hemorrhage. Neurotherapeutics. 2016;
13(2):439–49. Epub 2016/03/05. https://doi.org/10.1007/s13311-016-0424-8 PMID: 26935204;
PubMed Central PMCID: PMCPMC4824023.
29. Calle PA, Paridaens K, De Ridder LI, Buylaert WA. Failure of nimodipine to prevent brain damage in a
global brain ischemia model in the rat. Resuscitation. 1993; 25(1):59–71. Epub 1993/02/01. PMID:
8446788.
30. Laslo AM, Eastwood JD, Urquhart B, Lee TY, Freeman D. Subcutaneous administration of nimodipine
improves bioavailability in rabbits. J Neurosci Methods. 2004; 139(2):195–201. Epub 2004/10/19.
https://doi.org/10.1016/j.jneumeth.2004.04.030 PMID: 15488232.
31. Ma B, Zhang J. Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage.
Brain Res. 2006; 1078(1):182–8. Epub 2006/02/24. https://doi.org/10.1016/j.brainres.2006.01.045
PMID: 16492378.
32. Mohamed S, Riva R, Contin M. Simple and validated UHPLC-MS/MS analysis of nimodipine in plasma
and cerebrospinal fluid of patients with subarachnoid haemorrhage. J Chromatogr B Analyt Technol
Biomed Life Sci. 2016; 1028:94–9. Epub 2016/06/22. https://doi.org/10.1016/j.jchromb.2016.06.012
PMID: 27327399.
33. Hanggi D, Etminan N, Mayer SA, Aldrich EF, Diringer MN, Schmutzhard E, et al. Clinical Trial Protocol:
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and
Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Sub-
arachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing
TOxicity After SubarachNoid Hemorrhage)]. Neurocrit Care. 2019; 30(1):88–97. Epub 2018/07/18.
https://doi.org/10.1007/s12028-018-0575-z PMID: 30014184.
34. Ohlsson AL, Johansson BB. Environment influences functional outcome of cerebral infarction in rats.
Stroke. 1995; 26(4):644–9. Epub 1995/04/01. PMID: 7709412.
35. Radziwon-Balicka A, Degn M, Johansson SE, Warfvinge K, Edvinsson L. A novel multicolor flow-cytom-
etry application for quantitative detection of receptors on vascular smooth muscle cells. PLoS One.
2017; 12(10):e0186504. Epub 2017/10/31. https://doi.org/10.1371/journal.pone.0186504 PMID:
29084284; PubMed Central PMCID: PMCPMC5662092.
36. Johansson SE, Andersen XE, Hansen RH, Povlsen GK, Edvinsson L. Cerebrovascular endothelin-1
hyper-reactivity is associated with transient receptor potential canonical channels 1 and 6 activation
and delayed cerebral hypoperfusion after forebrain ischaemia in rats. Acta Physiol (Oxf). 2015; 214
(3):376–89. Epub 2015/05/06. https://doi.org/10.1111/apha.12519 PMID: 25939574.
37. Ansar S, Vikman P, Nielsen M, Edvinsson L. Cerebrovascular ETB, 5-HT1B, and AT1 receptor upregu-
lation correlates with reduction in regional CBF after subarachnoid hemorrhage. Am J Physiol Heart
Circ Physiol. 2007; 293(6):H3750–8. Epub 2007/09/18. https://doi.org/10.1152/ajpheart.00857.2007
PMID: 17873013.
38. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of
vehicle selection for drug formulation. Eur J Cancer. 2001; 37(13):1590–8. Epub 2001/08/31. PMID:
11527683.
39. Liu B, Gordon WP, Richmond W, Groessl T, Tuntland T. Use of solubilizers in preclinical formulations:
Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds. Eur J Pharm
Sci. 2016; 87:52–7. Epub 2015/10/27. https://doi.org/10.1016/j.ejps.2015.10.015 PMID: 26499309.
40. Zhao FK, Chuang LF, Israel M, Chuang RY. Cremophor EL, a widely used parenteral vehicle, is a
potent inhibitor of protein kinase C. Biochem Biophys Res Commun. 1989; 159(3):1359–67. Epub
1989/03/31. PMID: 2930566.
41. Henriksson M, Stenman E, Vikman P, Edvinsson L. Protein kinase C inhibition attenuates vascular ETB
receptor upregulation and decreases brain damage after cerebral ischemia in rat. BMC Neurosci. 2007;
8:7. Epub 2007/01/11. https://doi.org/10.1186/1471-2202-8-7 PMID: 17212812; PubMed Central
PMCID: PMCPMC1770924.
42. Ansar S, Edvinsson L. Subtype activation and interaction of protein kinase C and mitogen-activated pro-
tein kinase controlling receptor expression in cerebral arteries and microvessels after subarachnoid
hemorrhage. Stroke. 2008; 39(1):185–90. Epub 2007/11/23. https://doi.org/10.1161/STROKEAHA.
107.487827 PMID: 18032736.
43. Ansar S, Edvinsson L. Equal contribution of increased intracranial pressure and subarachnoid blood to
cerebral blood flow reduction and receptor upregulation after subarachnoid hemorrhage. Laboratory
U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after SAH
PLOS ONE | https://doi.org/10.1371/journal.pone.0215398 April 12, 2019 19 / 20
investigation. J Neurosurg. 2009; 111(5):978–87. Epub 2009/05/05. https://doi.org/10.3171/2007.3.
16738 PMID: 19408972.
44. Hartings JA, York J, Carroll CP, Hinzman JM, Mahoney E, Krueger B, et al. Subarachnoid blood acutely
induces spreading depolarizations and early cortical infarction. Brain. 2017; 140(10):2673–90. Epub
2017/10/04. https://doi.org/10.1093/brain/awx214 PMID: 28969382; PubMed Central PMCID:
PMCPMC5841026.
45. Kristiansen SB, Haanes KA, Sheykhzade M, Edvinsson L. Endothelin receptor mediated Ca(2+) signal-
ing in coronary arteries after experimentally induced ischemia/reperfusion injury in rat. J Mol Cell Car-
diol. 2017; 111:1–9. Epub 2017/08/02. https://doi.org/10.1016/j.yjmcc.2017.07.013 PMID: 28757442.
46. Hanggi D, Macdonald RL. Response by Hanggi and Macdonald to Letter Regarding Article, "Random-
ized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sus-
tained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to
Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])". Stroke. 2017; 48(4):
e114. Epub 2017/03/12. https://doi.org/10.1161/STROKEAHA.117.016603 PMID: 28283608.
47. Hanggi D, Etminan N, Aldrich F, Steiger HJ, Mayer SA, Diringer MN, et al. Randomized, Open-Label,
Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release
Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery
While Reducing Toxicity After Subarachnoid Hemorrhage]). Stroke. 2017; 48(1):145–51. Epub 2016/
12/10. https://doi.org/10.1161/STROKEAHA.116.014250 PMID: 27932607; PubMed Central PMCID:
PMCPMC5176000.
48. Maddahi A, Chen Q, Edvinsson L. Enhanced cerebrovascular expression of matrix metalloproteinase-9
and tissue inhibitor of metalloproteinase-1 via the MEK/ERK pathway during cerebral ischemia in the
rat. BMC Neurosci. 2009; 10:56. Epub 2009/06/06. https://doi.org/10.1186/1471-2202-10-56 PMID:
19497125; PubMed Central PMCID: PMCPMC2700114.
U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after SAH
PLOS ONE | https://doi.org/10.1371/journal.pone.0215398 April 12, 2019 20 / 20
